FN
FNAM.US Evolutionary Genomics Inc
- Market cap
- USD 1.33K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is FNAM.US undervalued?
Graham numberThe Graham number of Evolutionary Genomics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evolutionary Genomics Inc fundamental analysis
No fundamental analysis for Evolutionary Genomics Inc yet.
Evolutionary Genomics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company also develops Adapted Traits Platform, which is used to perform molecular evolution analysis to identify positively selected genes that may have an impact on traits of interest. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Cas…
Full company profileEvolutionary Genomics Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evolutionary Genomics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 799K | 348K | 263K | 222K | 32.7K | 115K | 123K | 12.5K | 0.00 | 0.00 | - |
| Gross Profit | 346K | 324K | 116K | 222K | 32.7K | 115K | -83.1K | -1.78M | -1.04M | -1.02M | - |
| Operating Income | -14.6K | -24.5K | -723K | -1.05M | -1.30M | -837K | -775K | -2.88M | -2.88M | -2.01M | - |
| EBITDA | -4.89K | -980K | -695K | -1.01M | -1.26M | -796K | -734K | -2.47M | -1.76M | -913K | - |
| Net Income | -19.3K | -27.1K | -286K | -1.15M | -540K | -1.10M | -793K | -1.71M | -2.79M | -1.93M | - |
| EPS | -0.15 | -0.21 | -0.06 | -0.20 | -0.09 | -0.19 | -0.13 | -0.29 | -0.48 | -0.30 | - |
| Balance Sheet | |||||||||||
| Total Assets | 991.00 | 1.36M | 3.17M | 6.40M | 5.40M | 4.39M | 4.24M | 3.99M | 2.93M | 2.35M | - |
| Total Liabilities | 78.2K | 13.7K | 254K | 4.56M | 4.00M | 3.99M | 4.58M | 5.82M | 7.33M | 3.92M | - |
| Shareholders' Equity | -77.2K | -13.7K | 2.92M | 1.84M | 1.40M | 404K | -334K | -1.83M | -4.40M | -1.57M | - |
| Cash & Short-term Investments | 641.00 | 729K | 262K | 2.12M | 1.17M | 160K | 87.1K | 216K | 214K | 577K | - |
| Total Debt | - | - | - | - | - | - | - | 2.25M | 3.74M | 3.74M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.2K | -25.8K | -590K | -1.11M | -1.18M | -749K | -626K | -2.30M | -1.58M | -641K | - |
| Capital Expenditure | 10.66 | 163.64 | 103K | 103K | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 3.00 | 0.00 |
| Free Cash Flow | -13.2K | -26.0K | -590K | -1.21M | -1.18M | -749K | -626K | -2.30M | -1.58M | -641K | - |
| Ratios | |||||||||||
| ROE | - | - | -9.8% | -62.6% | -38.4% | -272.2% | - | - | - | - | - |
| ROA | -1,943.5% | -2.0% | -9.0% | -18.0% | -10.0% | -25.0% | -18.7% | -42.9% | -95.3% | -82.2% | - |
| Net Profit Margin | -2.4% | -7.8% | -108.8% | -519.9% | -1,650.7% | -956.9% | -646.5% | -13,695.1% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Evolutionary Genomics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 269K | 0.05 | - |
| 2019 | USD 269K | 0.05 | - |
| 2018 | USD 242K | 0.04 | - |
| 2017 | USD 242K | 0.04 | - |
| 2016 | USD 197M | 33 | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:60.88264 on Oct 19, 2015.
Who owns Evolutionary Genomics Inc
- Insiders 32.65%
- Institutions 0.00%
- Public & others 67.35%
- Shares outstanding 6.66M
- Free float 4.48M
Evolutionary Genomics Inc company profile
- Company name
- Evolutionary Genomics Inc
- Ticker
- FNAM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 4220 Morning Star Drive, Castle Rock, CO, United States, 80108
- Phone
- 303 513 3510
- Website
- evolgen.com
About Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company also develops Adapted Traits Platform, which is used to perform molecular evolution analysis to identify positively selected genes that may have an impact on traits of interest. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Castle Rock, Colorado.
Evolutionary Genomics Inc management
3- Mr. Steve B. WarneckeChairman, CEO, President & CFO · born 1957
- Dr. Walter Messier Ph.D.Founder, CTO, Treasurer & Secretary · born 1956
- Ms. Virginia OrndorffFounder & Director · born 1951